COMPARISON
Desmopressin vs Lanreotide
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Desmopressin is authorised or registered in 9 and Lanreotide in 9 of the 10 registers read. Desmopressin: highest phase Phase 4 (after approval). Lanreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Desmopressin | Lanreotide | |
|---|---|---|
| Registered trials differs | 131 clinicaltrials.gov · 2026-10-03 | 125 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Desmopressin Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Desmopressin | placebo | Lanreotide | placebo |
|---|---|---|---|---|
| Headache | 7.0% | 3.9% | 10.7% | 9.4% |
| Nausea | 4.9% | 1.3% | 11.0% | 12.0% |
| Diarrhoea | 4.7% | 2.2% | 19.5% | 23.6% |
| Hypertension | 3.3% | 0.7% | 8.8% | 5.6% |
| Nasopharyngitis | 4.2% | 3.1% | - | - |
| Dizziness | 3.2% | 0.4% | - | - |
| Hyponatraemia | 3.1% | 1.2% | - | - |
| Pneumonia | 0.1% | 0.0% | - | - |
| Depression | 0.1% | 0.4% | - | - |
| Diverticulitis | 0.1% | 0.0% | - | - |
| Abdominal pain | - | - | 16.8% | 15.9% |
| Fatigue | - | - | 12.2% | 14.6% |
| Vomiting | - | - | 10.8% | 7.8% |
| Arthralgia | - | - | 8.0% | 8.2% |
| Back pain | - | - | 8.0% | 10.3% |
| Decreased appetite | - | - | 8.0% | 8.6% |
Trial register Desmopressin: 8 placebo-controlled trials; Lanreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Desmopressin side effects · Lanreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Desmopressin | Lanreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.